Nanopath Raises $25 Million in Series B Round

The Massachusetts diagnostics company will use the funding to advance its 15-minute vaginitis assay toward FDA clearance and commercial launch.

Updated on Nov. 12, 2026 in Tech

Bold flat-color editorial illustration of a single unlabeled biosensor chip with a gold grid beside two glass pipettes, set against a navy and cream field.
Massachusetts diagnostics company Nanopath raised $25 million in Series B financing, co-led by Norwest and SV Health Investors, to advance its 15-minute vaginitis test toward FDA clearance. AI Illustration. Upload story photo >

Live Poll

Would you trust a 15-minute at-home test for vaginal infections?

Nanopath secured $25 million in Series B financing, including $2 million in non-dilutive grant funding. Norwest and SV Health Investors' MedTech Convergence Fund co-led the round, with the Labcorp Venture Fund participating strategically.

Why it matters

The funding is intended to move a rapid point-of-care diagnostic toward market, with the company's plasmonic biosensing platform detecting genetic material without the copying step used in PCR testing. The round adds investors and a board observer from Labcorp Diagnostics to support clinical and commercial development.

The company's platform measures changes in how light interacts with tiny metal structures when a target molecule binds to a sensor, and the vaginitis assay returns results in 15 minutes. The stub does not provide assay sensitivity or specificity figures, and clinical performance data for the FDA submission has not been reported.

The players

Nanopath

Nanopath is a Massachusetts-based diagnostics company developing a plasmonic biosensing platform for clinical point-of-care testing.

Labcorp Venture Fund

The Labcorp Venture Fund is the corporate venture arm of Labcorp, the clinical laboratory company, which participated strategically in the round.

The details

Nanopath is developing a clinical diagnostic platform using plasmonic biosensing, which detects genetic material without the copying step used in polymerase chain reaction testing. The company received FDA Breakthrough Device designation for a rapid assay for complicated urinary tract infections and was awarded $4 million in grants from the NIH and NSF. The Series B proceeds will support manufacturing, the FDA 510(k) clinical study, and expanded clinical and commercial workforce.

Timeline

  1. 2022: Nanopath closed a $10 million Series A round.

  2. Approximately 2024 or earlier: Nanopath was awarded $4 million in NIH and NSF grants.

  3. Approximately 2025: Nanopath received FDA Breakthrough Device designation.

  4. November 12, 2026: Nanopath announced the $25 million Series B financing.

The Tech Race

Nanopath's approach of detecting genetic material without the copying step used in polymerase chain reaction (PCR) testing places it against the established molecular diagnostics standard. The Series B round signals investor interest in faster point-of-care alternatives to lab-based PCR workflows.

If the vaginitis assay reaches clearance and launch, patients could receive a diagnosis within 15 minutes rather than waiting for laboratory results. The stub does not indicate when the test would be available or what it would cost.

The takeaway

Point-of-care diagnostics that skip PCR's copying step could shorten the wait for test results, but clearance and commercial availability remain future milestones for Nanopath.

Further reading

Explore more Biotech coverage from across Massachusetts.

Live Poll

Would you trust a 15-minute at-home test for vaginal infections?